424 related articles for article (PubMed ID: 32890025)
1. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
Birzu C; Peyre M; Sahm F
Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
[TBL] [Abstract][Full Text] [Related]
2. Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets.
Maggio I; Franceschi E; Di Nunno V; Gatto L; Tosoni A; Angelini D; Bartolini S; Lodi R; Brandes AA
Diagnostics (Basel); 2021 Oct; 11(10):. PubMed ID: 34679551
[TBL] [Abstract][Full Text] [Related]
3. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
4. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas.
Cordova C; Kurz SC
Curr Oncol Rep; 2020 Jul; 22(8):84. PubMed ID: 32617743
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of genetic alterations and methylation classes in meningioma.
Berghoff AS; Hielscher T; Ricken G; Furtner J; Schrimpf D; Widhalm G; Rajky U; Marosi C; Hainfellner JA; von Deimling A; Sahm F; Preusser M
Brain Pathol; 2022 Mar; 32(2):e12970. PubMed ID: 35213082
[TBL] [Abstract][Full Text] [Related]
6. Biology and clinical management challenges in meningioma.
Mawrin C; Chung C; Preusser M
Am Soc Clin Oncol Educ Book; 2015; ():e106-15. PubMed ID: 25993161
[TBL] [Abstract][Full Text] [Related]
7. Genomic Landscape of Meningiomas.
Wang JZ; Nassiri F; Mawrin C; Zadeh G
Adv Exp Med Biol; 2023; 1416():137-158. PubMed ID: 37432625
[TBL] [Abstract][Full Text] [Related]
8. Meningioma: current updates on genetics, classification, and mouse modeling.
Szulzewsky F; Thirimanne HN; Holland EC
Ups J Med Sci; 2024; 129():. PubMed ID: 38571886
[TBL] [Abstract][Full Text] [Related]
9. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
10. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
[TBL] [Abstract][Full Text] [Related]
11. Innovative treatments for meningiomas.
Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetics of meningiomas: Building the roadmap towards personalized therapy.
Peyre M; Kalamarides M
Neurochirurgie; 2018 Mar; 64(1):22-28. PubMed ID: 25245924
[TBL] [Abstract][Full Text] [Related]
14. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management.
Daoud EV; Zhu K; Mickey B; Mohamed H; Wen M; Delorenzo M; Tran I; Serrano J; Hatanpaa KJ; Raisanen JM; Snuderl M; Cai C
Acta Neuropathol Commun; 2022 Apr; 10(1):56. PubMed ID: 35440040
[TBL] [Abstract][Full Text] [Related]
16. Current treatment options for meningioma.
Apra C; Peyre M; Kalamarides M
Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
[TBL] [Abstract][Full Text] [Related]
17. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
18. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
[TBL] [Abstract][Full Text] [Related]
19. Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.
Karsy M; Azab MA; Abou-Al-Shaar H; Guan J; Eli I; Jensen RL; Ormond DR
Neurosurg Focus; 2018 Jun; 44(6):E10. PubMed ID: 29852774
[TBL] [Abstract][Full Text] [Related]
20. Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review.
Okano A; Miyawaki S; Teranishi Y; Ohara K; Hongo H; Sakai Y; Ishigami D; Nakatomi H; Saito N
Neurol Med Chir (Tokyo); 2022 Aug; 62(8):347-360. PubMed ID: 35871574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
